Immunotherapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis
Article first published online: 7 NOV 2014
© 2014 British Society for Immunology
Clinical & Experimental Immunology
Volume 178, Issue 3, pages 447–458, December 2014
How to Cite
Zhou, F., Ciric, B., Zhang, G.-X. and Rostami, A. (2014), Immunotherapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis. Clinical & Experimental Immunology, 178: 447–458. doi: 10.1111/cei.12440
- Issue published online: 7 NOV 2014
- Article first published online: 7 NOV 2014
- Accepted manuscript online: 20 AUG 2014 12:56AM EST
- Manuscript Accepted: 13 AUG 2014
- National Multiple Sclerosis Society
Fig. S1. Gate scheme of dendritic cells (DCs). Bone marrow-derived DCs were cultured in complete medium with granulocyte–macrophage colony-stimulating factor (GM-CSF) (20 ng/ml).
Fig. S2. Maturation status of dendritic cells (DCs) induced by lipopolysaccharide (LPS) stimulation.
Fig. S3. Gate strategy of CD4+ T cells.
Fig. S4. Lipopolysaccharide (LPS)-stimulated dendritic cells (DCs)-induced immune tolerance is specific to myelin oligodendrocyte glycoprotein (MOG) peptide.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.